228 related articles for article (PubMed ID: 38400859)
1. Pt(IV) Complexes in the Search for Novel Platinum Prodrugs with Promising Activity.
Aher S; Zhu J; Bhagat P; Borse L; Liu X
Top Curr Chem (Cham); 2024 Feb; 382(1):6. PubMed ID: 38400859
[TBL] [Abstract][Full Text] [Related]
2. Multiaction Pt(IV) Carbamate Complexes Can Codeliver Pt(II) Drugs and Amine Containing Bioactive Molecules.
Babu T; Sarkar A; Karmakar S; Schmidt C; Gibson D
Inorg Chem; 2020 Apr; 59(7):5182-5193. PubMed ID: 32207294
[TBL] [Abstract][Full Text] [Related]
3. Chlorambucil-conjugated platinum(IV) prodrugs to treat triple-negative breast cancer in vitro and in vivo.
Ma ZY; Wang DB; Song XQ; Wu YG; Chen Q; Zhao CL; Li JY; Cheng SH; Xu JY
Eur J Med Chem; 2018 Sep; 157():1292-1299. PubMed ID: 30195239
[TBL] [Abstract][Full Text] [Related]
4. Investigation of the Inertness to Hydrolysis of Platinum(IV) Prodrugs.
Ritacco I; Mazzone G; Russo N; Sicilia E
Inorg Chem; 2016 Feb; 55(4):1580-6. PubMed ID: 26812023
[TBL] [Abstract][Full Text] [Related]
5. Emerging platinum(iv) prodrugs to combat cisplatin resistance: from isolated cancer cells to tumor microenvironment.
Wang Z; Deng Z; Zhu G
Dalton Trans; 2019 Feb; 48(8):2536-2544. PubMed ID: 30633263
[TBL] [Abstract][Full Text] [Related]
6. Potent Chlorambucil-Platinum(IV) Prodrugs.
Aputen AD; Elias MG; Gilbert J; Sakoff JA; Gordon CP; Scott KF; Aldrich-Wright JR
Int J Mol Sci; 2022 Sep; 23(18):. PubMed ID: 36142383
[TBL] [Abstract][Full Text] [Related]
7. Beyond mere DNA damage: Recent progress in platinum(IV) anticancer complexes containing multi-functional axial ligands.
Deng Z; Zhu G
Curr Opin Chem Biol; 2023 Jun; 74():102303. PubMed ID: 37075513
[TBL] [Abstract][Full Text] [Related]
8. Complexes of oxoplatin with rhein and ferulic acid ligands as platinum(iv) prodrugs with high anti-tumor activity.
Tan MX; Wang ZF; Qin QP; Zou BQ; Liang H
Dalton Trans; 2020 Feb; 49(5):1613-1619. PubMed ID: 31942585
[TBL] [Abstract][Full Text] [Related]
9. Synthesis, Characterization and Biological Investigation of the Platinum(IV) Tolfenamato Prodrug-Resolving Cisplatin-Resistance in Ovarian Carcinoma Cell Lines.
Barth MC; Häfner N; Runnebaum IB; Weigand W
Int J Mol Sci; 2023 Mar; 24(6):. PubMed ID: 36982792
[TBL] [Abstract][Full Text] [Related]
10. Platinum(IV) Prodrugs.
Venkatesh V; Sadler PJ
Met Ions Life Sci; 2018 Feb; 18():. PubMed ID: 29394022
[TBL] [Abstract][Full Text] [Related]
11. Stability, Reduction, and Cytotoxicity of Platinum(IV) Anticancer Prodrugs Bearing Carbamate Axial Ligands: Comparison with Their Carboxylate Analogues.
Chen S; Yao H; Zhou Q; Tse MK; Gunawan YF; Zhu G
Inorg Chem; 2020 Aug; 59(16):11676-11687. PubMed ID: 32799457
[TBL] [Abstract][Full Text] [Related]
12. An Anticancer Pt
Kostrhunova H; Petruzzella E; Gibson D; Kasparkova J; Brabec V
Chemistry; 2019 Apr; 25(20):5235-5245. PubMed ID: 30740808
[TBL] [Abstract][Full Text] [Related]
13. Effect of the aniline fragment in Pt(II) and Pt(IV) complexes as anti-proliferative agents. Standard reduction potential as a more reliable parameter for Pt(IV) compounds than peak reduction potential.
Leal J; Santos L; Fernández-Aroca DM; Cuevas JV; Martínez MA; Massaguer A; Jalón FA; Ruiz-Hidalgo MJ; Sánchez-Prieto R; Rodríguez AM; Castañeda G; Durá G; Carrión MC; Barrabés S; Manzano BR
J Inorg Biochem; 2021 May; 218():111403. PubMed ID: 33730639
[TBL] [Abstract][Full Text] [Related]
14. Hitting Multiple Cellular Targets in Triple-Negative Breast Cancer Using Dual-Action Cisplatin(IV) Prodrugs for Safer Synergistic Chemotherapy.
Date T; Kuche K; Chaudhari D; Ghadi R; Sahel DK; Chitkara D; Jain S
ACS Biomater Sci Eng; 2022 Jun; 8(6):2349-2362. PubMed ID: 35522530
[TBL] [Abstract][Full Text] [Related]
15. Are Pt(IV) Prodrugs That Release Combretastatin A4 True Multi-action Prodrugs?
Schmidt C; Babu T; Kostrhunova H; Timm A; Basu U; Ott I; Gandin V; Brabec V; Gibson D
J Med Chem; 2021 Aug; 64(15):11364-11378. PubMed ID: 34342437
[TBL] [Abstract][Full Text] [Related]
16. Multi-Acting Mitochondria-Targeted Platinum(IV) Prodrugs of Kiteplatin with α-Lipoic Acid in the Axial Positions.
Savino S; Marzano C; Gandin V; Hoeschele JD; Natile G; Margiotta N
Int J Mol Sci; 2018 Jul; 19(7):. PubMed ID: 30011897
[TBL] [Abstract][Full Text] [Related]
17. Platinum(iv) anticancer prodrugs - hypotheses and facts.
Gibson D
Dalton Trans; 2016 Aug; 45(33):12983-91. PubMed ID: 27214873
[TBL] [Abstract][Full Text] [Related]
18. Understanding the Role of Axial Ligands in Modulating the Biopharmaceutical Outcomes of Cisplatin(IV) Derivatives.
Date T; Kuche K; Ghadi R; Kumar P; Jain S
Mol Pharm; 2022 May; 19(5):1325-1337. PubMed ID: 35437994
[TBL] [Abstract][Full Text] [Related]
19. Synthesis and characterization of Pt(IV) fluorescein conjugates to investigate Pt(IV) intracellular transformations.
Song Y; Suntharalingam K; Yeung JS; Royzen M; Lippard SJ
Bioconjug Chem; 2013 Oct; 24(10):1733-40. PubMed ID: 23957697
[TBL] [Abstract][Full Text] [Related]
20. A Pt(IV) Prodrug Combining Chlorambucil and Cisplatin: a Dual-Acting Weapon for Targeting DNA in Cancer Cells.
Montagner D; Tolan D; Andriollo E; Gandin V; Marzano C
Int J Mol Sci; 2018 Nov; 19(12):. PubMed ID: 30486477
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
